phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

Recent district court rulings set an alarming precedent that calls into question the authority of the U.S. Food and Drug Administration (FDA) to determine the safety and effectiveness of new medicines.

The FDA is the gold standard for determining whether a medicine is safe and effective. The FDA evaluates volumes of scientific data prior to approval and continues to assess the risks and benefits long after a medicine is approved. These rigorous evaluations give American patients the confidence that what they’re picking up at the pharmacy is safe and effective.

PhRMA has serious concerns with any court substituting its opinion for the FDA’s expert approval decision-making. Patients and their doctors rely on the FDA to serve as an expert and trusted arbiter of what medicines are safe for use so they can make the most informed health care decisions. Moreover, undermining the FDA’s longstanding authority given to them by Congress to approve drugs would have a chilling effect on the research and development ecosystem. Biopharmaceutical researchers and scientists need certainty that FDA approvals will be upheld so they can make the long-term investments required to develop new medicines and ultimately get them approved for use by patients.

At a time when medical innovation has never been more promising, it is vital we have a legal and policy environment that fosters the development of new treatments and cures and protects patients’ access to the medicines they need. We will continue to explore all policy and legal options to ensure the FDA’s approval authority is protected.

Jim Stansel

James Stansel is Executive Vice President, General Counsel and Corporate Secretary of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he is responsible for overseeing the organization’s legal team and science and regulatory advocacy department in supporting PhRMA’s policy, advocacy and science priorities and in the development of sound legal policies impacting the pharmaceutical industry.

Jim Stansel

How the biosimilars user fee program supports competition and patients

October 26, 2026

Mass compounding puts patients at risk

July 16, 2026

Advancing patient care: A look at new medicines approved in 2025

January 30, 2026

Knockoffs of FDA-approved drugs put patients at risk

December 1, 2025

PDUFA: Essential to America’s edge in drug development and patient access

October 31, 2025

Major drug compounder is spending millions on misleading Super Bowl ad

February 5, 2025

More oversight needed of unapproved medicines that threaten patients’ health

August 1, 2024

The use of real-world data in drug development

May 13, 2024

New analysis: Accelerated approval pathway is changing lives in underserved communities

April 30, 2024

Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high

January 23, 2024

Florida’s importation plan puts patients in danger

January 5, 2024

The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings

December 19, 2023

Decentralized clinical trials and the future of drug development

August 9, 2023

How FDA’s modernization strategy could improve drug development

June 20, 2023

Setting the record straight on accelerated approval

May 22, 2023

What you should know about real-world evidence and drug development

December 19, 2022

Three things to know about the accelerated approval pathway

December 12, 2022

PDUFA and BsUFA reauthorizations are wins for patients

October 5, 2022

Word of the Month: Biomarkers and surrogate endpoints

July 11, 2022

Ensuring timely reauthorization of PDUFA and BsUFA

May 11, 2022

The accelerated approval pathway: Helping patients with serious or life-threatening diseases

March 17, 2022

The importance of timely PDUFA and BsUFA reauthorization

February 3, 2022

ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients

January 26, 2022

Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition

September 28, 2021

Meeting Tomorrow: Looking ahead to PDUFA VII

September 27, 2021

The impact of monoclonal antibodies and COVID-19 recovery

September 2, 2021

PDUFA VII is critical for future biopharmaceutical innovation and for patients

August 23, 2021

How strengthening the biosimilar marketplace benefits patients

May 18, 2021

The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research

May 12, 2021

2020 FDA approvals show innovation despite COVID-19 pandemic challenges

January 26, 2021

Nearly 400 cell and gene therapies in development to target a broad range of diseases

March 10, 2020

ICYMI: 2019 brings innovative medicines to patients

January 17, 2020

PhRMA comments to Congress on Cures 2.0 call to action

December 18, 2019

Guest Post: Using the patient voice to go boldly

May 30, 2019

IP Explained: How Hatch-Waxman successfully balances affordability and innovation

May 22, 2019

Guest post: Hearing from patients on Rare Disease Day

February 28, 2019

Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation

February 28, 2019

Why state drug importation pilot programs don’t work

February 8, 2019

Putting 2018 medicine approvals in context

January 23, 2019

FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies

October 16, 2018

Balancing innovation and competition in the biologics marketplace

October 11, 2018

New analysis shows that more medicines worldwide are available to U.S. patients

June 5, 2018

Spending on medicines grew less than one percent in 2017

April 19, 2018

Rare Disease Day: Unmet need inspires innovation

February 28, 2018

Innovation comes in many forms, including new and expanded uses of existing medicines

January 29, 2018

ICYMI: Why 2017 medicine approvals matter

January 12, 2018

New surveys find payers and providers want more data from biopharmaceutical companies

December 6, 2017

Supporting opportunities for enhanced competition in the marketplace

November 22, 2017

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

October 12, 2017

Opportunities to build upon enhanced competition for medicines in the marketplace

July 27, 2017

Why reauthorization of PDUFA matters

July 13, 2017

A critical opportunity to prevent prescription drug abuse

June 2, 2017

Guest Post: The importance of a modern FDA in drug discovery

March 22, 2017

FDA should remain the authority on the safety and effectiveness of medicines

FDA

FDA should remain the authority on the safety and effectiveness of medicines

April 12, 2023

FDA should remain the authority on the safety and effectiveness of medicines

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list